Nucala Now Available for Severe Asthma – Monthly Prescribing Reference (registration)


Monthly Prescribing Reference (registration)

Nucala Now Available for Severe Asthma
Monthly Prescribing Reference (registration)
GlaxoSmithKline announced the launch of Nucala (mepolizumab) subcutaneous injection for the treatment of patients aged ?12 years with severe asthma with an eosinophilic phenotype. Nucala, the first biologic add-on therapy approved for this condition, …
GSK Announces NucalaB. (mepolizumab), Now Available In The Us For Sub-Group Of CNNMoney
GSK Says Nucala Available In U.S. For Sub-group Of Patients With Severe AsthmaNasdaq

all 4 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.